What Solinfec Treats: Main Uses and Benefits

Solinfec (Ketoconazole oral tablet) is a systemic antifungal agent primarily reserved for use against serious, deep-seated fungal infections that necessitate systemic management.

---

Addressing Endemic and Systemic Mycoses

This medication is relevant for addressing certain severe systemic fungal conditions, such as Blastomycosis, Histoplasmosis, and Coccidioidomycosis (Valley fever). It is applied when the pathogenic burden is systemic, and may assist with addressing the widespread infectious processes associated with deep tissue involvement.

---

Managing Severe Constitutional Symptoms

This systemic therapy assists with managing the symptoms related to systemic imbalance related to these serious infections, which may include persistent fever and profound malaise. In this therapeutic context, the treatment contributes to easing the overall symptom load, which helps patients cope more steadily during difficult episodes of heightened discomfort.

“This systemic antifungal may be part of managing the severe body-wide manifestations that accompany deep fungal diseases.”

---

Treatment Option for Complex and Refractory Cases

Solinfec is a relevant therapeutic option when patients have failed to respond to, or are unable to tolerate, other established antifungal therapies. Its use is applied in clinical settings marked by temporary physiological imbalance, supporting the patient by assisting with maintaining functional well-being during prolonged symptomatic periods.

---

Quick Fact: Use in Systemic Imbalance

Feature	Description
Primary Use	Management of endemic systemic mycoses
Symptom Focus	Persistent fever, profound malaise, constitutional fatigue
Clinical Context	Alternative therapy for refractory or complex fungal cases
General Benefit	Contributes to easing the overall symptom load

Regulatory References

1. FDA-Approved Indications for Ketoconazole Oral Tablet

Who Can and Cannot Use Solinfec (Ketoconazole)

Solinfec, whose active ingredient is oral ketoconazole, is an antifungal medicine typically reserved for treating severe systemic fungal infections in adult patients who cannot use or have failed therapy with safer alternative medications. Its use is limited due to the potential for serious adverse effects, notably hepatotoxicity and heart rhythm abnormalities.

Eligibility Status	Specific Populations/Conditions
Populations for Whom Use is Contraindicated
Formal Contraindications	Patients with acute or chronic liver disease, including abnormal liver function tests. Patients with a known allergy or hypersensitivity to ketoconazole or any component of the formulation.
Specific Drug Interactions	Co-administration with numerous drugs that prolong the QT interval or are highly metabolized by the same liver enzymes (e.g., dofetilide, quinidine, cisapride, methadone) is strictly prohibited due to risk of life-threatening cardiac events.
Populations for Whom Use is Restricted
Hepatic/Cardiac	Requires weekly liver function monitoring and careful assessment in patients with existing heart rhythm abnormalities (QT prolongation risk).
Endocrine	Adrenal function should be monitored in patients with adrenal insufficiency or during periods of prolonged physical stress.
Age-Related	Use in pediatric patients is not established in all regions and requires careful risk assessment.
Physiological States	Use is generally not recommended during pregnancy and is contraindicated during breastfeeding due to potential risks to the infant.

Before initiating treatment, a healthcare provider must confirm the absence of specific contraindications and establish that the potential benefits clearly outweigh the known risks for the patient.

Solinfec (ketoconazole) is a potent inhibitor of the enzyme CYP3A4 and a P-glycoprotein inhibitor, which can significantly raise the blood levels of many co-administered medicines that are metabolized by this pathway. This action is the basis for a large number of documented drug-drug interactions, some of which are classified as major or potentially life-threatening and must be strictly avoided.

Medicines Contraindicated for Co-administration

Co-administration with Solinfec is contraindicated for specific medicines where an increase in concentration may lead to severe adverse reactions, including a serious heart rhythm issue known as QT prolongation or enhanced sedation. Examples of contraindicated medicines include certain heart rhythm drugs (e.g., dofetilide, quinidine, dronedarone, ranolazine), some sedatives (e.g., oral midazolam, alprazolam, triazolam), and ergot derivatives (e.g., ergotamine) due to the risk of ergotism. Certain cholesterol-lowering medicines (statins) and specific calcium channel blockers are also in this category.

Other Significant Interactions

Solinfec requires an acidic environment for proper absorption. Medicines that reduce stomach acid (such as antacids, H2 blockers, and proton pump inhibitors) can significantly decrease Solinfec's effectiveness. Antacids must be separated from Solinfec intake by at least one hour before or two hours after the dose. Additionally, drugs that strongly induce CYP3A4 (e.g., rifampicin, phenytoin, St. John's wort) can decrease Solinfec levels, potentially reducing its therapeutic effect. Your healthcare provider must be informed of all prescription, over-the-counter, and herbal products being taken.

Inhibition of Fungal Ergosterol Synthesis (Primary Mechanism)

The central action of Solinfec is the inhibition of the fungal enzyme Lanosterol 14α-demethylase (CYP51A1). By binding to the enzyme’s heme iron, the drug blocks the organism's essential pathway for creating ergosterol, the core structural lipid of the fungal cell membrane. This molecular blockade is the foundational step that influences the drug's overall biological activity against the fungal organism.

※ Mechanism of Cellular Disruption

The depletion of ergosterol, combined with the accumulation of non-functional sterol precursors, results in a critical loss of structural integrity and fluidity in the fungal cell membrane. This cellular compromise leads to increased membrane permeability and the leakage of vital contents, resulting in the cessation of the organism's growth and replication (a fungistatic consequence). This physiological consequence is the direct outcome of the initial enzymatic blockade.

️ Modulation of Host Steroidogenesis (Secondary Effect)

Solinfec exhibits a secondary pharmacodynamic effect by interfering with specific host P450 enzymes (17α-hydroxylase and 17,20-lyase) involved in human steroid production. This off-target interaction can transiently modulate the host's endocrine pathways, which may result in a temporary decrease in the synthesis of glucocorticoids and androgens as the drug is distributed systemically.

Solinfec: Official Administration Guidelines

Solinfec is administered orally as a 200 mg tablet, intended for systemic action against deep-seated fungal infections. Its usage is defined by regimens focused on a single daily dose taken over a long-term course. The general duration of therapy for endemic systemic fungal infections is often 6 months or continued until the active fungal process has subsided.

Patient Group	Starting Dose	Maximum Dose / Frequency
Adults	200 mg once daily	400 mg once daily
Pediatric (≥ 2 years)	3.3 to 6.6 mg/kg	Once daily

Administration Requirements

A critical procedural instruction is that the tablet must be taken with a meal to achieve maximal oral absorption into the bloodstream. Because the drug requires an acidic environment for dissolution, patients utilizing acid-reducing agents (such as antacids) must take Solinfec at least 1 hour before or 2 hours after the acid reducer to prevent absorption interference. In cases where gastric acidity is low, administration alongside an acidic beverage may be employed to ensure the dose is adequately absorbed. No specific dose adjustment is recommended for patients with renal impairment.

Solinfec: Research Evidence Overview

Solinfec in Conditions Characterized by Fluctuating or Episodic Manifestations

Research examining Solinfec has been applied in studies exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations. These studies primarily focused on outcomes related to physical discomfort and outcomes describing episodic or acute changes. The research scenarios often involved studies conducted during periods of increased symptom activity, exploring short-term symptom changes.

Studies explored what happens during episodes where symptoms become more noticeable. Studies explored outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort. For instance, data show patterns related to how symptoms evolved in the observed populations during defined time intervals. This research provides insight into short-term changes and contributes to understanding how patients reported their experience when symptoms were active.

However, the evidence is limited, and research is ongoing. Follow-up durations were limited in many studies, and long-term effects are not fully established. While the compound was studied for conditions involving periods of heightened symptoms, the certainty remains low regarding sustained changes. These findings describe group patterns, not personal outcomes, and studies help show what has been observed so far, but comparative evidence is often lacking.

Solinfec in Conditions Associated with Acute or Disruptive Episodes

Solinfec was also evaluated in research contexts involving fluctuating or unstable symptoms in conditions associated with acute or disruptive episodes. Research examined outcomes capturing phases of heightened symptom activity and outcomes linked to inflammatory or irritative states. These studies were relevant in trials assessing short-term or episodic symptom patterns.

Research examined outcomes related to daily functioning or activity level during acute phases, and data show patterns related to these outcomes. Studies report changes measured during the study period, particularly when observing responses over defined time intervals. Findings contribute to understanding how patients reported their experience with episodes that may be associated with physiological strain or stress. This evidence contributes to the broader evidence landscape related to symptom patterns in these specific scenarios.

Data are still emerging, and research exploring temporary physiological imbalance is continuing. Results apply only to the populations studied, and sample sizes were modest in some research. There is limited information for long-term outcomes, and comparative evidence is lacking, particularly across various types of acute episodes. Subgroup findings are uncertain, meaning the evidence quality varies across studies, and data for certain groups remain insufficient.

Evidence in Specific Populations

Research for Solinfec in specific populations, such as those with certain functional limitations or those presenting with cycles of stability and flare-ups, was associated with observational settings evaluating daily-life functioning. Studies monitored symptom intensity or variability.

Studies monitored patterns related to physical discomfort and systemic or functional imbalance in certain groups. Research describes how symptoms evolved in the observed populations, and this information was observed in some studies that included individuals with conditions marked by functional limitations.

However, long-term effects are not fully established, and evidence quality varies across studies. Data for certain groups remain insufficient, and the results reflect the specific conditions under which they were conducted. Research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References Clinical Guideline for the Management of Conditions with Acute or Disruptive Episodes (Section 4: Acute Pharmacological Interventions)

Common questions about Solinfec (FAQ)

Q: What is Solinfec actually used for, besides the main thing?

The official therapeutic purpose of Solinfec is restricted to treating serious systemic fungal infections. Regulatory documents reserve its use for situations where other treatment options are unavailable or not tolerated, which is due to the potential for serious side effects. The official indication, therefore, focuses exclusively on these deep-seated fungal problems.

Q: Is Solinfec the same class of drug as [Competitor Drug Name]?

According to official product information, Solinfec contains the active ingredient ketoconazole, which belongs to the azole antifungal class of medications. This classification denotes the specific group of synthetic compounds used to counter the proliferation of fungal pathogens.

Q: Can Solinfec be taken with over-the-counter pain relievers?

Official safety information indicates that the active ingredient may interact with certain commonly available pain medications. This potential interaction can alter the metabolism of the pain reliever. Official product labeling recommends informing a healthcare provider of all prescription and over-the-counter products being taken.

Q: Are there any specific vitamins or supplements that interact with Solinfec?

The official product label specifically names the herbal supplement St. John’s wort as a known interaction. Co-administration is documented as potentially decreasing the absorption of the drug, which could reduce its intended therapeutic effectiveness.

Q: What does 'contraindicated' mean in relation to Solinfec?

When a medicine is officially labeled as contraindicated, it means that its use is strictly prohibited under certain patient conditions or alongside specific medications. This prohibition is due to the high and potentially life-threatening risk of serious adverse effects if the drug is used inappropriately.

Q: Why might Solinfec be discontinued by a healthcare professional?

Official regulatory documents require that treatment be interrupted if certain laboratory tests, such as those measuring liver enzymes (ALT), show specific increases above acceptable limits. Discontinuation is also indicated if a patient develops signs of liver injury.

Q: Can men and women use Solinfec the same way?

While the drug targets fungal infections, it can have a secondary pharmacodynamic effect by transiently decreasing the synthesis of steroid hormones in the body. This interaction has been noted in official documents to potentially result in specific reported side effects, such as breast pain or tenderness in men.

Q: Are there any specific laboratory tests required before starting Solinfec?

Official guidelines require that specific laboratory tests be obtained before starting treatment, known as a baseline assessment. These tests include those for liver function (such as ALT and AST) and for viral hepatitis, as part of the mandated safety monitoring protocol.

Q: Does Solinfec have different warnings for different age groups?

Yes, the official regulatory label contains specific warnings that differ by age group. For example, the label notes that cases of serious liver injury (hepatitis) have been reported in children, contributing to the requirement for careful risk assessment in the pediatric population.

Q: What is the purpose of the black box warning on Solinfec (if applicable)?

The official regulatory document includes a Boxed Warning, which is the strongest type of warning required by the FDA. Its purpose is to highlight the drug's association with two serious adverse reactions: the potential for fatal liver injury (hepatotoxicity) and the risk of life-threatening heart rhythm issues (QT prolongation).

Q: Is Solinfec used for acute or chronic conditions?

Official administration guidelines describe the typical duration of therapy as a long-term course, often lasting six months or longer. This duration suggests the drug is used for chronic or persistent infections rather than acute, short-term treatment episodes.

Q: What is the chemical makeup of the active ingredient in Solinfec?

The active ingredient is Ketoconazole, which is chemically classified as an imidazole derivative. Official documents provide the molecular formula as C26 H28 Cl2 N4 O4.

Q: Why is Solinfec indicated for a specific age range?

The official indication includes a restricted use for the pediatric population. This limitation is due to safety concerns that necessitate careful risk assessment, including reports of liver injury (hepatitis) observed in children.

Q: Is Solinfec a new type of medicine?

The active ingredient in Solinfec, ketoconazole, is not considered a new type of medicine. Regulatory documents note that the compound was first developed in 1977, establishing it as one of the original medications in the azole antifungal class.

Q: Will Solinfec show up on a drug test?

There is documented information from clinical laboratories suggesting that the active ingredient, ketoconazole, may potentially cause a false positive result in certain types of urine drug screening tests. This possibility is related to its metabolic structure.

Q: What happens if I miss a scheduled time for Solinfec?

Official regulatory guidance addresses how to handle a missed dose, stating that patients should not take a double dose to make up for a missed one. Specific instructions for dosing adjustments when a dose is missed are provided in the patient information leaflet.

Q: What is the list of ingredients in Solinfec, besides the active one?

Official regulatory documents provide a list of inactive ingredients, or excipients, used in the oral tablet formulation. These include colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and methylcellulose.

Q: Are there restrictions on driving or operating machinery while using Solinfec?

The regulatory side effect profile includes reports of drowsiness and dizziness as possible adverse reactions. Due to the potential for these effects to impair concentration, official product labeling includes warnings regarding operating machinery or driving while using the medication.

Q: Does official information for Solinfec include warnings about alcohol?

Yes, official labeling contains a warning against the consumption of alcohol while on treatment. This is due to the potential for alcohol to increase the risk of serious liver problems. Additionally, combining the drug with alcohol may trigger an adverse reaction characterized by flushing and nausea.

Q: Is Solinfec a prescription-only medicine?

Solinfec oral tablets are legally classified as a prescription-only medicine in major regulatory jurisdictions worldwide. In the US, it is labeled as ℞-only, meaning it requires authorization from a qualified healthcare provider to be dispensed.

Q: Is there any known interaction between Solinfec and grapefruit?

Yes, official product information contains a warning against the use of grapefruit and grapefruit juice. This is because these products may interact with the drug’s metabolism, potentially increasing the amount of the drug in the bloodstream and raising the risk of side effects.

Q: What should I do if I think I'm having a rare side effect from Solinfec?

Official safety documents require the immediate reporting of any signs of a serious adverse effect. Key symptoms noted in regulatory information that should be reported promptly include yellowing of the skin or eyes (jaundice), unusual tiredness, or dark urine.

Q: How long does Solinfec stay in your system after stopping it?

The drug is eliminated from the body in two phases. The terminal phase has an elimination half-life of approximately 7.5 to 8 hours. The majority of the drug (over 95%) is removed from the body through hepatic metabolism.

Q: Is the research for Solinfec based on animal or human studies?

The evidence supporting the drug's use and safety is derived from a body of research that includes both human clinical studies and animal studies. These studies are typically utilized during the development and approval process to assess the drug's effects and safety profile.

How to Store and Dispose of Solinfec?

Solinfec (Ketoconazole oral tablets) requires adherence to specific regulatory requirements to maintain its stability and ensure proper handling. This information is derived from official governmental labeling.

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, maintaining 15 C to 30 C (59 F to 86 F).
Container Protection	The medicine must be kept in a tight, light-resistant container and protected from moisture.
Safety	The container must be kept tightly closed and stored out of the reach of children.

Disposal Instructions

Unused or expired Solinfec must be managed according to official disposal protocols. Patients should not flush these tablets down a toilet or pour them down a sink unless specifically authorized. Instead, unused medicine should be disposed of in alignment with local community regulations or drug take-back programs.